DR REDDYS LABORATORIES
|
DR REDDYS LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 67.81 | 334.41 | 270.55 | 131.16 | 117.28 |
| CEPS(Rs) | 89.08 | 84.51 | 69.12 | 40.24 | 38.23 |
| DPS(Rs) | 8.00 | 40.00 | 40.00 | 30.00 | 25.00 |
| Book NAV/Share(Rs) | 400.54 | 1,686.06 | 1,388.98 | 1,145.98 | 1,052.59 |
| Tax Rate(%) | 25.45 | 22.54 | 25.48 | 28.71 | 32.32 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 26.18 | 28.32 | 25.74 | 17.49 | 20.32 |
| EBIT Margin(%) | 24.39 | 26.32 | 25.10 | 14.65 | 15.65 |
| Pre Tax Margin(%) | 23.53 | 25.71 | 24.52 | 14.21 | 15.14 |
| PAT Margin (%) | 17.54 | 19.91 | 18.27 | 10.13 | 10.25 |
| Cash Profit Margin (%) | 22.76 | 25.16 | 23.34 | 15.54 | 16.70 |
| Performance Ratios | |||||
| ROA(%) | 13.41 | 16.08 | 15.01 | 8.08 | 8.21 |
| ROE(%) | 18.61 | 21.76 | 21.36 | 11.93 | 11.82 |
| ROCE(%) | 23.25 | 26.86 | 26.22 | 14.59 | 15.49 |
| Asset Turnover(x) | 0.76 | 0.81 | 0.82 | 0.80 | 0.80 |
| Sales/Fixed Asset(x) | 1.13 | 1.12 | 1.01 | 0.96 | 0.92 |
| Working Capital/Sales(x) | 2.72 | 1.84 | 2.08 | 2.69 | 2.96 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.88 | 0.89 | 0.99 | 1.04 | 1.08 |
| Receivable days | 95.44 | 99.54 | 103.01 | 98.60 | 95.74 |
| Inventory Days | 75.27 | 73.12 | 73.65 | 81.57 | 77.11 |
| Payable days | 96.23 | 108.56 | 108.07 | 99.98 | 100.14 |
| Valuation Parameters | |||||
| PER(x) | 16.87 | 3.68 | 3.42 | 32.83 | 38.50 |
| PCE(x) | 12.84 | 14.57 | 13.37 | 21.40 | 23.63 |
| Price/Book(x) | 2.86 | 3.65 | 3.33 | 3.76 | 4.29 |
| Yield(%) | 0.70 | 0.65 | 0.87 | 0.70 | 0.55 |
| EV/Net Sales(x) | 2.99 | 3.68 | 3.11 | 3.37 | 3.99 |
| EV/Core EBITDA(x) | 10.12 | 11.66 | 10.35 | 17.08 | 18.29 |
| EV/EBIT(x) | 12.26 | 13.96 | 12.37 | 23.00 | 25.53 |
| EV/CE(x) | 2.55 | 3.40 | 3.11 | 3.21 | 3.68 |
| M Cap / Sales | 2.92 | 3.67 | 3.12 | 3.33 | 3.94 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 16.54 | 13.54 | 14.50 | 13.11 | 8.74 |
| Core EBITDA Growth(%) | 9.26 | 19.22 | 74.14 | 2.18 | 34.63 |
| EBIT Growth(%) | 8.01 | 19.07 | 96.10 | 5.93 | 50.23 |
| PAT Growth(%) | 2.64 | 23.75 | 106.52 | 11.83 | -3.67 |
| EPS Growth(%) | -79.72 | 23.60 | 106.27 | 11.83 | -3.79 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.14 | 0.07 | 0.06 | 0.18 | 0.17 |
| Current Ratio(x) | 1.92 | 2.59 | 2.38 | 1.82 | 1.79 |
| Quick Ratio(x) | 1.37 | 1.92 | 1.82 | 1.30 | 1.23 |
| Interest Cover(x) | 28.15 | 43.09 | 43.36 | 32.96 | 30.73 |
| Total Debt/Mcap(x) | 0.05 | 0.02 | 0.02 | 0.05 | 0.04 |
Compare Financial Ratios of peers of DR REDDYS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DR REDDYS LABORATORIES | ₹104,128.9 Cr | 0.2% | -2.7% | 2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹426,566.0 Cr | 1.2% | 5.3% | 0.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,594.0 Cr | -0.7% | -2.1% | 12.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹125,826.0 Cr | -3.2% | 4.1% | 20.2% | Stock Analytics | |
| CIPLA | ₹123,504.0 Cr | -0.2% | -6.7% | 1.8% | Stock Analytics | |
| MANKIND PHARMA | ₹92,336.1 Cr | -1.3% | -8.8% | -14.7% | Stock Analytics | |
DR REDDYS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DR REDDYS LABORATORIES | 0.2% |
-2.7% |
2% |
| SENSEX | 1.4% |
2% |
10.2% |
You may also like the below Video Courses
